Clinical 177Lu-PSMA-617 radioligand therapy (RLT) is applied in advanced-stage prostate cancer. However, to the best of our knowledge murine models to study the biologic effects of various activity levels have not been established. The aim of this study was to optimize specific and total activity for 177Lu-PSMA-617 RLT in a syngeneic model of murine prostate cancer. Methods: Murine-reconstituted, oncogene-driven prostate cancer cells (0.1 × 106) (RM1), transduced to express human prostate-specific membrane antigen (PSMA), were injected into the left flank of C57Bl6 immunocompetent mice. RLT was performed by administering a single tail vein injection of 177Lu-PSMA-617 at different formulations for specific (60 MBq at high, 62 MBq/nmol; intermediate, 31 MBq/nmol; or low 15 MBq/nmol specific activity) or total activity (30, 60, or 120 MBq). Organ distribution was determined by ex vivo γ-counter measurement. DNA double-strand breaks were measured using anti-gamma-H2A.X (phospho S139) immunohistochemistry. Efficacy was assessed by serial CT tumor volumetry and 18F-FDG PET metabolic volume. Toxicity was evaluated 4 wk after the start of RLT. Results: Mean tumor-to-kidney ratios ± SEM were 19 ± 5, 10 ± 5, and 2 ± 0 for high, intermediate, and low (each n = 3) specific activity, respectively. Four of 6 (67%) mice treated with intermediate or high specific activity and none of 6 (0%) mice treated with low specific activity or formulation demonstrated significant DNA double-strand breaks (≥5% γ-H2A.X-positive cells). High when compared with intermediate or low specific activity resulted in a lower mean ± SEM tumor load by histopathology (vital tissue, 4 ± 2 vs. 8 ± 3 mm2; n = 3 vs. 6), day-4 18F-FDG PET (metabolic volume, 87 ± 23 vs. 118 ± 14 mm3; n = 6 vs. 12), and day-7 CT (volume, 323 ± 122 vs. 590 ± 46 mm3; n = 3 vs. 6; P = 0.039). 177Lu-PSMA-617 (120 MBq) with high specific activity induced superior tumor growth inhibition (P = 0.021, n = 5/group) without subacute hematologic toxicity (n = 3/group). Conclusion: 177Lu-PSMA-617 (120 MBq) and high specific activity resulted in the highest efficacy in a syngeneic model of murine prostate cancer. The model will be useful for studying the effects of PSMA-directed RLT combined with potentially synergistic pharmacologic approaches.
Clinical 177Lu-PSMA-617 radioligand therapy (RLT) is applied in advanced-stage prostate cancer. However, to the best of our knowledge murine models to study the biologic effects of various activity levels have not been established. The aim of this study was to optimize specific and total activity for 177Lu-PSMA-617 RLT in a syngeneic model of murine prostate cancer. Methods:Murine-reconstituted, oncogene-driven prostate cancer cells (0.1 × 106) (RM1), transduced to express humanprostate-specific membrane antigen (PSMA), were injected into the left flank of C57Bl6 immunocompetent mice. RLT was performed by administering a single tail vein injection of 177Lu-PSMA-617 at different formulations for specific (60 MBq at high, 62 MBq/nmol; intermediate, 31 MBq/nmol; or low 15 MBq/nmol specific activity) or total activity (30, 60, or 120 MBq). Organ distribution was determined by ex vivo γ-counter measurement. DNA double-strand breaks were measured using anti-gamma-H2A.X (phospho S139) immunohistochemistry. Efficacy was assessed by serial CT tumor volumetry and 18F-FDG PET metabolic volume. Toxicity was evaluated 4 wk after the start of RLT. Results: Mean tumor-to-kidney ratios ± SEM were 19 ± 5, 10 ± 5, and 2 ± 0 for high, intermediate, and low (each n = 3) specific activity, respectively. Four of 6 (67%) mice treated with intermediate or high specific activity and none of 6 (0%) mice treated with low specific activity or formulation demonstrated significant DNA double-strand breaks (≥5% γ-H2A.X-positive cells). High when compared with intermediate or low specific activity resulted in a lower mean ± SEM tumor load by histopathology (vital tissue, 4 ± 2 vs. 8 ± 3 mm2; n = 3 vs. 6), day-4 18F-FDG PET (metabolic volume, 87 ± 23 vs. 118 ± 14 mm3; n = 6 vs. 12), and day-7 CT (volume, 323 ± 122 vs. 590 ± 46 mm3; n = 3 vs. 6; P = 0.039). 177Lu-PSMA-617 (120 MBq) with high specific activity induced superior tumor growth inhibition (P = 0.021, n = 5/group) without subacute hematologic toxicity (n = 3/group). Conclusion: 177Lu-PSMA-617 (120 MBq) and high specific activity resulted in the highest efficacy in a syngeneic model of murine prostate cancer. The model will be useful for studying the effects of PSMA-directed RLT combined with potentially synergistic pharmacologic approaches.
Authors: Kambiz Rahbar; Matthias Schmidt; Alexander Heinzel; Elisabeth Eppard; Axel Bode; Anna Yordanova; Michael Claesener; Hojjat Ahmadzadehfar Journal: J Nucl Med Date: 2016-04-07 Impact factor: 10.057
Authors: S J Knox; M L Goris; K Trisler; R Negrin; T Davis; T M Liles; A Grillo-López; P Chinn; C Varns; S C Ning; S Fowler; N Deb; M Becker; C Marquez; R Levy Journal: Clin Cancer Res Date: 1996-03 Impact factor: 12.531
Authors: Johanna Svensson; Johan Mölne; Eva Forssell-Aronsson; Mark Konijnenberg; Peter Bernhardt Journal: Nucl Med Biol Date: 2012-03-24 Impact factor: 2.408
Authors: Linda Villard; Anna Romer; Nicolas Marincek; Philippe Brunner; Michael T Koller; Christian Schindler; Quinn K T Ng; Helmut R Mäcke; Jan Müller-Brand; Christoph Rochlitz; Matthias Briel; Martin A Walter Journal: J Clin Oncol Date: 2012-03-05 Impact factor: 44.544
Authors: Clemens Kratochwil; Frederik L Giesel; Melsa Stefanova; Martina Benešová; Marcus Bronzel; Ali Afshar-Oromieh; Walter Mier; Matthias Eder; Klaus Kopka; Uwe Haberkorn Journal: J Nucl Med Date: 2016-03-16 Impact factor: 10.057
Authors: Kambiz Rahbar; Hojjat Ahmadzadehfar; Clemens Kratochwil; Uwe Haberkorn; Michael Schäfers; Markus Essler; Richard P Baum; Harshad R Kulkarni; Matthias Schmidt; Alexander Drzezga; Peter Bartenstein; Andreas Pfestroff; Markus Luster; Ulf Lützen; Marlies Marx; Vikas Prasad; Winfried Brenner; Alexander Heinzel; Felix M Mottaghy; Juri Ruf; Philipp Tobias Meyer; Martin Heuschkel; Maria Eveslage; Martin Bögemann; Wolfgang Peter Fendler; Bernd Joachim Krause Journal: J Nucl Med Date: 2016-10-20 Impact factor: 10.057
Authors: Woosuk Kim; Thuc M Le; Liu Wei; Soumya Poddar; Jimmy Bazzy; Xuemeng Wang; Nhu T Uong; Evan R Abt; Joseph R Capri; Wayne R Austin; Juno S Van Valkenburgh; Dalton Steele; Raymond M Gipson; Roger Slavik; Anthony E Cabebe; Thotsophon Taechariyakul; Shahriar S Yaghoubi; Jason T Lee; Saman Sadeghi; Arnon Lavie; Kym F Faull; Owen N Witte; Timothy R Donahue; Michael E Phelps; Harvey R Herschman; Ken Herrmann; Johannes Czernin; Caius G Radu Journal: Proc Natl Acad Sci U S A Date: 2016-03-28 Impact factor: 11.205
Authors: Kristell L S Chatalic; Sandra Heskamp; Mark Konijnenberg; Janneke D M Molkenboer-Kuenen; Gerben M Franssen; Marian C Clahsen-van Groningen; Margret Schottelius; Hans-Jürgen Wester; Wytske M van Weerden; Otto C Boerman; Marion de Jong Journal: Theranostics Date: 2016-04-12 Impact factor: 11.556
Authors: Wolfgang P Fendler; Svenja Reinhardt; Harun Ilhan; Andreas Delker; Guido Böning; Franz J Gildehaus; Christian Stief; Peter Bartenstein; Christian Gratzke; Sebastian Lehner; Axel Rominger Journal: Oncotarget Date: 2017-01-10
Authors: Sangeeta Ray Banerjee; Vivek Kumar; Ala Lisok; Jian Chen; Il Minn; Mary Brummet; Srikanth Boinapally; Michael Cole; Ethel Ngen; Bryan Wharram; Cory Brayton; Robert F Hobbs; Martin G Pomper Journal: Eur J Nucl Med Mol Imaging Date: 2019-08-10 Impact factor: 9.236
Authors: Katharina Lückerath; Andreea D Stuparu; Liu Wei; Woosuk Kim; Caius G Radu; Christine E Mona; Jeremie Calais; Matthew Rettig; Robert E Reiter; Johannes Czernin; Roger Slavik; Ken Herrmann; Matthias Eiber; Wolfgang P Fendler Journal: J Nucl Med Date: 2018-03-30 Impact factor: 10.057
Authors: Jia Wang; Alejandra Rios; Ksenia Lisova; Roger Slavik; Arion F Chatziioannou; R Michael van Dam Journal: Nucl Med Biol Date: 2019-12-17 Impact factor: 2.408
Authors: Kyle Current; Catherine Meyer; Clara E Magyar; Christine E Mona; Joel Almajano; Roger Slavik; Andreea D Stuparu; Chloe Cheng; David W Dawson; Caius G Radu; Johannes Czernin; Katharina Lueckerath Journal: Clin Cancer Res Date: 2020-01-13 Impact factor: 12.531
Authors: Andreea D Stuparu; Joseph R Capri; Catherine A L Meyer; Thuc M Le; Susan L Evans-Axelsson; Kyle Current; Mark Lennox; Christine E Mona; Wolfgang P Fendler; Jeremie Calais; Matthias Eiber; Magnus Dahlbom; Johannes Czernin; Caius G Radu; Katharina Lückerath; Roger Slavik Journal: J Nucl Med Date: 2020-12-04 Impact factor: 10.057
Authors: Sarah Piron; Jeroen Verhoeven; Emma De Coster; Benedicte Descamps; Ken Kersemans; Leen Pieters; Anne Vral; Christian Vanhove; Filip De Vos Journal: Sci Rep Date: 2021-11-19 Impact factor: 4.379